Loading…
Palvella Therapeutics, Inc. is projected to rise to $198.79 by 2027, a +32% move from its current price of $150.19. PVLA is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/31/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 1 | $143.56 | $150.26 | $157.28 | +0.05% |
| Aug 2 | $140.95 | $150.34 | $160.36 | +0.10% |
| Aug 3 | $138.99 | $150.41 | $162.78 | +0.15% |
| Aug 4 | $137.37 | $150.49 | $164.86 | +0.20% |
| Aug 5 | $135.97 | $150.56 | $166.73 | +0.25% |
| Aug 6 | $134.72 | $150.64 | $168.45 | +0.30% |
| Aug 7 | $133.58 | $150.71 | $170.05 | +0.35% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $133.58 | $150.71 | $170.05 | +0.35% |
| Week 2 | $127.51 | $151.24 | $179.39 | +0.70% |
| Week 3 | $123.14 | $151.77 | $187.05 | +1.05% |
| Week 4 | $119.64 | $152.30 | $193.87 | +1.40% |
| Week 5 | $116.69 | $152.83 | $200.17 | +1.76% |
| Week 6 | $114.12 | $153.36 | $206.11 | +2.11% |
| Week 7 | $111.83 | $153.90 | $211.79 | +2.47% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of angiokeratomas and other mTOR-driven skin diseases; and QTORIN pitavastatin for the treatment of disseminated superficial actinic porokeratosis.
The company is based in Wayne, Pennsylvania.
Palvella Therapeutics, Inc. (PVLA) is a clinical-stage biopharmaceutical company in Healthcare. PVLA trades at $143.94 and has a market cap of $2.06B. It is ranked 2002 by market capitalization.
A major floor 36.5% below — a decisive break under it would weaken the trend.
The nearest floor, 25.0% below — buyers have tended to step in here.
The nearest ceiling, 4.7% above — a clean break opens room to run.
A major ceiling 22.9% above — clearing it would confirm fresh momentum.
Key PVLA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of PVLA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $143.08 | Buy | $144.81 | Buy |
| MA 10 | $142.61 | Buy | $143.88 | Buy |
| MA 20 | $144.77 | Buy | $141.89 | Buy |
| MA 50 | $129.03 | Buy | $134.08 | Buy |
| MA 100 | $126.42 | Buy | $124.91 | Buy |
| MA 200 | $109.18 | Buy | $107.87 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 56.58 | Neutral |
| Stoch RSI (14) | 63.54 | Neutral |
| CCI (20) | 82.35 | Neutral |
| Williams %R (14) | -21.31 | Info |
| MACD (12,26,9) | -0.89 | Sell |
| ROC (12) | 0.34 | Buy |
| Bollinger %B (20,2) | 0.71 | Neutral |
| Stochastic %K (14) | 78.69 | Neutral |
| TRIX (15) | 0.52 | Buy |
| Awesome (5,34) | 6.01 | Buy |
| Ultimate (7,14,28) | 60.90 | Neutral |
| Momentum (10) | 2.42 | Buy |
| Aroon Osc (25) | -4.00 | Sell |
| Hull MA (9) | 145.14 | Buy |
| ADX (14) | 14.04 | Neutral |
| ATR (14) | 6.04 | Info |
The near-term technical picture shows bullish sentiment. RSI14 is 50, and the stock trades with the 50-day moving average at $125.57 above the 200-day moving average at $106.59, suggesting a constructive trend. Support is at $102.19 and resistance at $157.24, with a 30-day price range from $99.10 to $209.07.
Annualized volatility sits at 100%, underscoring substantial near-term movement potential.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $76.43 | $150.19 | $199.35 | 0% | Neutral | |
| $148.86 | $198.79 | $285.67 | +32% | Bullish | |
| $152.10 | $213.70 | $325.21 | +42% | Bullish | |
| $161.72 | $237.17 | $377.09 | +58% | Bullish | |
| $195.56 | $298.03 | $491.39 | +98% | Bullish | |
| $226.48 | $357.65 | $608.44 | +138% | Bullish | |
| $314.04 | $512.91 | $897.13 | +242% | Bullish | |
| $359.27 | $605.92 | $1,086.57 | +303% | Bullish | |
| $322.48 | $560.94 | $1,029.08 | +273% | Bullish | |
| $353.86 | $634.31 | $1,188.35 | +322% | Bullish | |
| $611.51 | $1,264.02 | $2,582.13 | +742% | Bullish | |
| $1,044.14 | $2,320.30 | $5,336.70 | +14.4x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $76.43 | $150.19 | $175.70 | +0.00% |
| August 2026 | $126.14 | $150.16 | $184.47 | -0.02% |
| September 2026 | $130.16 | $157.17 | $197.33 | +4.67% |
| October 2026 | $129.44 | $158.09 | $201.90 | +0.59% |
| November 2026 | $122.60 | $151.16 | $195.71 | -4.39% |
| December 2026 | $122.28 | $152.08 | $199.35 | +0.61% |
Click any year to see its month-by-month PVLA forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, PVLA is projected to trade between $76.43 and $199.35, averaging $150.19 — a potential gain of 0% from today's $150.19. Price action looks broadly range-bound.
Palvella Therapeutics, Inc.'s 2027 outlook centres on $198.79, within a $148.86 to $285.67 range. That is up +32% on the projected 2026 average. That marks a +32% change versus current levels. Buyers look set to stay in control over this stretch.
By 2028, PVLA could reach as high as $325.21, with a base case around $213.70 and support toward $152.10 — roughly +42% from $150.19. Momentum favours further upside here.
Expect PVLA to range from $161.72 to $377.09 through 2029. The $237.17 average target implies a +58% move from current prices. That is up +11% on the projected 2028 average. Buyers look set to stay in control over this stretch.
The PVLA price prediction for 2030 points to an average of $298.03 (low $195.56, high $491.39) — a potential gain of +98% on today's $150.19. Momentum favours further upside here.
In 2031, PVLA is projected to trade between $226.48 and $608.44, averaging $357.65 — a potential gain of +138% from today's $150.19. That is up +20% on the projected 2030 average. Buyers look set to stay in control over this stretch.
Palvella Therapeutics, Inc.'s 2032 outlook centres on $512.91, within a $314.04 to $897.13 range. That is up +43% on the projected 2031 average. That marks a +242% change versus current levels. Momentum favours further upside here.
By 2033, PVLA could reach as high as $1,086.57, with a base case around $605.92 and support toward $359.27 — roughly +303% from $150.19. Buyers look set to stay in control over this stretch.
Expect PVLA to range from $322.48 to $1,029.08 through 2034. The $560.94 average target implies a +273% move from current prices. That is -7% versus the projected 2033 average. Momentum favours further upside here.
The PVLA price prediction for 2035 points to an average of $634.31 (low $353.86, high $1,188.35) — a potential gain of +322% on today's $150.19. Buyers look set to stay in control over this stretch.
In 2040, PVLA is projected to trade between $611.51 and $2,582.13, averaging $1,264.02 — a potential gain of +742% from today's $150.19. That is up +99% on the projected 2035 average. Momentum favours further upside here.
Palvella Therapeutics, Inc.'s 2050 outlook centres on $2,320.30, within a $1,044.14 to $5,336.70 range. That is up +84% on the projected 2040 average. That marks a +14.4x change versus current levels. Buyers look set to stay in control over this stretch.
Investing $1,000 in PVLA today (≈ 6.658233 PVLA) could be worth
$15,449.12
+$14,449.12 (+1445%) by 2050 · US Dollar
Based on the average projected PVLA price of $2,320.3 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in PVLAwould be worth at today's price.
$1,000 invested in PVLA on Jul 30, 2025 (≈ 26.709403 PVLA) would be worth
$4,011.49
+$3,011.49 (+301.1%) today · 4.01× · US Dollar
Based on a PVLA entry price of $37.44 vs. today's $150.19.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $143.21 | $1,048.78 | +4.9% |
| 1 month ago | $152.82 | $982.79 | -1.7% |
| 3 months ago | $126.84 | $1,184.09 | +18.4% |
| 6 months ago | $76.69 | $1,958.4 | +95.8% |
| 1 year ago | $37.44 | $4,011.49 | +301.1% |
| All time (5.0y) ago | $281.6 | $533.35 | -46.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our PVLA forecast.
Our base-case forecast reaches $300.00 around 2031.
Implied market cap at $300.00: $4.3B
The multi-year forecast points to a bullish trajectory after a neutral start in 2026. For 2026, the average price is $143.94 with a min of $76.43 and a max of $197.12 (ROI 0, sentiment NEUTRAL). From 2027 onward, the path strengthens: 2027 avg $192.43, 2028 avg $201.26, 2029 avg $220.84, 2030 avg $270.33 (ROI 87.8%, sentiment BULLISH).
The outlook rises further in later years, with 2031 avg $320.42 (ROI 122.6%), 2032 avg $503.50 (ROI 249.8%), 2033 avg $592.02 (ROI 311.3%), 2034 avg $519.90 (ROI 261.2%), and 2035 avg $609.83 (ROI 323.7%). In the far horizon, 2040 shows avg $1,216.37 (ROI 745%), and 2050 shows avg $2,097.93 (ROI 1357.5%). The max forecasts reach $2,668.95 in 2040 and $4,825.25 in 2050, with bullish sentiment prevailing.
These are estimates and not guarantees, reflecting potential upside alongside substantial uncertainty.
Tap a question to reveal the answer.
The forecast shows min $167.34, avg $270.33, max $468.67; ROI 87.8; sentiment BULLISH.
The forecast indicates a bullish path from 2027 onward with rising averages and positive ROI, though 2026 is neutral. For 2030 the avg is $270.33 with an 87.8% ROI, and longer horizons show substantial upside potential; these are estimates, not guarantees.
Yes. The 2033 forecast lists a max of $1,126.31, which exceeds $1,000.
Current price is $143.94; market cap is $2.06B.
The 30-day range is $99.10 to $209.07.
Palvella Therapeutics, Inc. Community Discussion
0Share your Palvella Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.